Catabasis Pharmaceuticals Profile

1.54
USD 0.02  1.28%
83%
57%

Acquisition by Edward Hibben of 100000 shares of Catabasis Pharmaceuticals subject to Rule 16b-3

Catabasis Pharmaceuticals Inc insider trading alert for grant of stock option (right to buy) by Edward Hibben, Chief Business Officer, on February 9, 2018. This event was filed by Catabasis Pharmaceuticals with SEC on 2018-02-09. Statement of changes in beneficial ownership - SEC Form 4 [view details]   

Catabasis Pharmaceuticals Summary

Catabasis Pharmaceuticals Inc (CATB) is traded on NASDAQ General Markets in USA. It is located in MASSACHUSETTS, U.S.A and employs 38 people. Catabasis Pharmaceuticals is listed under Pharmaceutical Products category by Fama And French industry classification.The company currently falls under 'Micro-Cap' category with current market capitalization of 36.01 M. Catabasis Pharmaceuticals Inc conducts business under Healthcare sector and is part of Pharmaceutical Products industry. This company has 23.08 M outstanding shares of which 217.42 K shares are currently shorted by private and institutional investors with about 0.6 trading days to cover. N/A currently holds about 21.71 M in cash with (29.18 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.94.
Check Catabasis Pharmaceuticals Probability Of Bankruptcy

Ownership Allocation (%)

Top Holders

Major Institutional Holders

InstituionSecurity TypeTotal SharesValue
Sv Health Investors LlcCommon Shares2.9 M4.3 M
Clarus Ventures LlcCommon Shares2.8 M4.1 M
View Catabasis Pharmaceuticals Diagnostics

Selected Catabasis Pharmaceuticals Inc Income Statement Over Time

Consolidated Income    Earning Before Interest and Taxes EBIT    Net Income    

Key Fundamentals

Catabasis Pharmaceuticals Against Markets

Current Ratings

Catabasis Pharmaceuticals 30 Days Performance Scores
Risk Adjusted
Performance Score (0 to 100)
2 
Chance of
Financial Distress (0 to 100%)
< 16% 
Equity ratings for Catabasis Pharmaceuticals Inc are calculated dynamically based on Macroaxis scoring framework. Click here to learn more
Catabasis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic products based on safely metabolized and rationally targeted linker drug discovery platform in the United States. Catabasis Pharmaceuticals, Inc. was founded in 2008 and is based in Cambridge, Massachusetts. Catabasis Pharmaceuticals operates under Biotechnology classification in USA and traded on NASDAQ General Markets exchange. It employs 38 people. more
Fama & French Pharmaceutical Products
Pharmaceutical Products
Fama & French Classification
NameCatabasis Pharmaceuticals Inc
CEOJill MilneAll Leadership
Analyst Consensus
Piotroski F Score
Macroaxis Advice
InstrumentUSA Stock Stocks Directory
LocationMASSACHUSETTS, U.S.A
Business AddressBuilding 1400E
ExchangeNASDAQ General Markets
CUSIP14875P107
SectorHealthcare
IndustryPharmaceutical Products
BenchmarkDOW
Websitewww.catabasis.com
Contact Number617 349 1971
CurrencyUSD - US Dollar

Recommendations

Catabasis Pharmaceuticals Analyst Recommendations
Target PriceAdvice# of Analysts
8.25Buy4Odds
Catabasis Pharmaceuticals Inc current and past analyst recommendations published by number of research institutions as well as average analyst consensus
Catabasis Pharmaceuticals Analyst Advice  

Opportunities

Explore Investment Opportunities
Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked.
Explore Investing Ideas  

Earnings

Catabasis Pharmaceuticals Earnings Estimates
EPSEstimate Date
Quarterly Estimate-0.49March 1, 2017
Catabasis Pharmaceuticals Inc normalized analysts earnings estimates for actual as well as projected forward EPS values taken as an average expert opinion over time
Earnings Estimate  

Directors

Catabasis Pharmaceuticals Corporate Directors
Jean George Director, MBA
Michael Kishbauch Director, MBA
Burt Adelman Director, Ph.D